Teva's AZILECT R 1 Mg Tablets Meet End Points In ADAGIO Phase III Trial
Added: 17 èþíÿ 2008
Last relative articles:
- Invest In A Future Without Dementia
- Advance Towards Early Alzheimer's Diagnosis
- Suven Life Sciences Initiates Phase I Clinical Trials In Europe Of SUVN-502 For Alzheimer's Disease
- Elan And Wyeth Announce Encouraging Top-line Results From Phase 2 Clinical Trial Of Bapineuzumab For Alzheimer's Disease
- Molecular Imaging Sheds New Light On Progression Of Alzheimer's Disease
- Known Genetic Risk For Alzheimer's In Whites Also Places Blacks At Risk
- UQ-US Team Targets Faster Alzheimer's Detection
- Researchers Link Memory Loss To Poor Diet
- New Campaign Launched In Wales: Are You Worried About Your Memory?
- The APCs Of Nerve Cell Function
Comments: [0] / Post comment:
05 Jan 2009 17:15:25
Pfizer CEO open to big buyout deals; FDA considers updates to ... - FiercePharma
Pfizer CEO open to big buyout deals; FDA considers updates to ... FiercePharma, DC - Release » Bernstein Research analyst Dr. Aaron Gal expects that Teva Pharmaceutical industries' Azilect drug for Parkinson's will peak at $450 million in ...
04 Jan 2009 19:04:40
Analyst lowers Teva's Azilect expectations - Globes
Analyst lowers Teva's Azilect expectations Globes, Israel - Bernstein Research thinks peak sales for Azilect will be far lower than Teva's own estimates. Bernstein Research analyst Dr. Aaron (Ronny) Gal forecasts ...
30 Dec 2008 11:10:01
Teva Introduces New Thinner 29-Gauge Needle For COPAXONE® Pre ... - Medical News Today (press release)
Teva Introduces New Thinner 29-Gauge Needle For COPAXONE Pre ... Medical News Today (press release), UK - Therapies developed by Teva Neuroscience include COPAXONE for relapsing-remitting multiple sclerosis and AZILECT (rasagiline tablets) for the treatment of ...
25 Dec 2008 02:38:55
Long-Term Investor - Investor's Business Daily (subscription)
Long-Term Investor Investor's Business Daily (subscription) - Teva's products include Copaxone for multiple sclerosis and Azilect for Parkinson's disease. It also makes specialty pharmaceutical products, ...
24 Dec 2008 13:09:52
Teva Introduces New Thinner 29-Gauge Needle for COPAXONE® Pre ... - dBusinessNews Kansas City (press release)
Teva Introduces New Thinner 29-Gauge Needle for COPAXONE Pre ... dBusinessNews Kansas City (press release), MO - Therapies developed by Teva Neuroscience include COPAXONE for relapsing-remitting multiple sclerosis and AZILECT (rasagiline tablets) for the treatment ...
17 Dec 2008 17:16:08
Teva Pharmaceutical (TEVA) NewsBite - Buy Ratings Boost TEVA - Market Intelligence Center
Teva Pharmaceutical (TEVA) NewsBite - Buy Ratings Boost TEVA Market Intelligence Center, VA - Teva Pharmaceutical (NasdaqNM: TEVA) opened at $43.02. So far today, the stock has hit a low of $42.96 and a high of $43.26. TEVA is now trading at $43.20, ... Citi Initiates Coverage on Teva Pharmaceutical (TEVA) with a Buy ...
16 Dec 2008 23:10:08
Parkinsons Disease Market analysis and forecasts, 2008-2012, 2017 ... - Live-PR.com (Pressemitteilung)
Parkinsons Disease Market analysis and forecasts, 2008-2012, 2017 ... Live-PR.com (Pressemitteilung), Austria - Do you know the market Potential of Teva Lundbecks Azilect ? Do you know the Neuroprotective properties of Gene cell Therapy compounds? ...
15 Dec 2008 10:03:06
"En Lundbeck queremos abordar las enfermedades mentales en su ... - El Global
"En Lundbeck queremos abordar las enfermedades mentales en su ... El Global, Spain - Por otro lado, Azilect (rasagilina DCI), para el párkinson, está dando muy buenos resultados, sobre todo con la publicación del estudio Adagio, ...
Source: http://elglobal.net/articulo.asp